Bioinformatics for cancer management in the post-genome era

Technology in Cancer Research and Treatment

Volumn 5, Issue 2, 2006, Pages 169-175

  Katoh, Masuko ^a   Katoh, Masaru ^b  

^a M and M Medical Biolnformatics   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Array CGH; Bioinformatics; Biomarker; Epigenetics; Microarray; Oncogenomics; Oncoproteomics; Personalized medicine

Indexed keywords

APC PROTEIN; BETA CATENIN; BEVACIZUMAB; BIOLOGICAL MARKER; BRCA1 PROTEIN; CETUXIMAB; CYTOTOXIC AGENT; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 18; FRIZZLED PROTEIN; GEFITINIB; IMATINIB; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MONOCLONAL ANTIBODY; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; T CELL FACTOR PROTEIN; TRASTUZUMAB; UVOMORULIN; WNT PROTEIN;

APOPTOSIS; BIOINFORMATICS; BREAST CANCER; CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; DNA LIBRARY; DNA MICROARRAY; ENVIRONMENTAL FACTOR; EPIGENETICS; FAMILIAL CANCER; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC TRANSFECTION; GENOMICS; HELICOBACTER PYLORI; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMIA; LYMPHOMA; MASS SPECTROMETRY; METABOLOMICS; PEUTZ JEGHERS SYNDROME; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEOMICS; RETINOBLASTOMA; REVIEW; RNA STABILITY; SENESCENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TRANSCRIPTOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 33645961885     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460600500208     Document Type: Review

References (74)

1. Fearon, E. R., Vogelstein, B. A Genetic Model for Colorectal Tumorigenesis. Cell 61, 759-767 (1990).
2. Sugimura, T., Terada, M., Yokota, J., Hirohashi, S., Wakabayashi, K. Multiple Genetic Alterations in Human Carcinogenesis. Environ. Health Perspect. 98, 5-12 (1992).
3. Katoh, M., Terada, M. Oncogenes and Tumor Suppressor Genes. In Gastric Cancer, pp. 196-208. Eds., M. Nishi. Springer-Verlag, Tokyo (1993).
4. Katoh, M., Katoh, M. Pharmacogenomics on Gastric Cancer. Cancer Biol. Ther. 3, 566-567 (2004).
5. Katoh, M. WNT and FGF Gene Clusters. Int. J. Oncol. 21, 1269-1273 (2002).
6. Garciadiego-Cazares, D., Rosales, C., Katoh, M., Chimal-Monroy, J. Coordination of Chondrocyte Differentiation and Joint Formation by α5β1 Integrin in the Developing Appendicular Skeleton. Development 131, 4735-4742 (2004).
7. Katoh, Y., Katoh, M. Hedgehog Signaling in Gastric Cancer. Cancer Biol. Ther. 4, 1050-1054 (2005).
8. Katoh, M. WNT2b: Comparative Integromics and Clinical Application. Int. J. Mol. Med. 16, 1103-1108 (2005).
9. Swain, R. K., Katoh, M., Medina, A., Steinbeisser, H. Xenopus Frizzled-4S, A Splicing Variant Of Xfz4, is a Context-dependent Activator and Inhibitor of Wnt/β-catenin Signaling. Cell Commun. Signal 3, 12 (2005).
10. Katoh, M. Regulation of WNT Signaling Molecules by Retinoic Acid During Neuronal Differentiation in NT2 Cells: Threshold Model of WNT Action. Int. J. Mol. Med. 10, 683-687 (2002).
11. Katoh, M., Katoh, M. Identification and Characterization of Human BCL9L Gene and Mouse Bcl91 Gene In Silica. Int. J. Mol. Med. 12, 643-649 (2003).
12. Katoh, M. Paradignshift in Gene-finding Method: From Benchtop Approach to Desk-top Approach. Int. J. Mol. Med. 10, 677-682 (2002).
13. Persidis, A. Bioinformatics. Nat. Biotech. 17, 828-830 (1999).
14. Malkin, D., Li, F. P., Strong, L. C., et al. Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms. Science 250, 1233-1238 (1990).
15. Lee, W. H., Bookstein, R., Hong, F., et al. Human Retinoblastoma Susceptibility Gene: Cloning, Identification, and Sequence. Science 235, 1394-1399 (1987).
16. Nishisho, I., Nakamura, Y., Miyoshi, Y., et al. Mutations of Chromosome 5q21 Genes in FAP and Colorectal Cancer Patients. Science 253, 665-669 (1991).
17. Miki, Y., Swensen, J., Shattuck-eidens, D., et al. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science 266, 66-71 (1994).
18. Guilford, P., Hopkins, J., Harraway, J., et al. E-cadherin Germline Mutations in Familial Gastric Cancer. Nature 392, 402-405 (1998).
19. Eng, C., Hampel, H., de la Chapelle, A. Genetic Testing for Cancer Predisposition. Annu. Rev. Med. 52, 371-400 (2001).
20. Soussi, T., Beroud, C. Assessing TP53 Status in Human Tumours to Evaluate Clinical Outcome. Nat. Rev. Cancer 1, 233-240 (2001).
21. Parsonnet, J., Friedman, G. D., Vandersteen, D. P., et al. Helicobacter pylori Infection and the Risk of Gastric Carcinoma. N. Engl. J. Med. 325, 1127-1131 (1991).
22. Bruix, J., Barrera, J. M., Calvet, X., et al. Prevalence of Antibodies to Hepatitis C Virus in Spanish Patients with Hepatocellular Carcinoma and Hepatic Cirrhosis. Lancet 2, 1004-1006 (1989).
23. Meisels, A., Morin, C., Casas-cordero, M., Rabreau, M. Human Papillomavirus (HPV) Venereal Infections and Gynecologic Cancer. Pathol. Annu. 18 Pt 2, 277-293 (1983).
24. Zhao, X., Li, C., Paez, J. G., et al. An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays. Cancer Res. 64, 3060-3071 (2004).
25. Bertone, P., Stolc, V., Royce, T. E., et al. Global Identification of Human Transcribed Sequences with Genome Tiling Arrays. Science 306, 2242-2246 (2004).
26. Kallioniemi, O. P. Biochip Technologies in Cancer Research. Ann. Med. 33, 142-147 (2001).
27. Derisi, J., Penland, L., Brown, P. O., et al. Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer. Nat. Genet. 14, 457-460 (1996).
28. Khan, J., Simon, R., Bittner, M., et al. Gene Expression Profiling of Alveolar Rhabdomyosarcoma with cDNA Microarrays. Cancer Res. 58, 5009-5013 (1998).
29. Katoh, M., Katoh, M. CLDN23 Gene, Frequently Down-regulated in Intestinal-type Gastric Cancer, is a Novel Member of CLAUD1N Gene Family. Int. J. Mol. Med. 11, 683-689 (2003).
30. Katoh, M., Katoh, M. MGC29506 Gene, Frequently Down-regulated in Intestinal-type Gastric Cancer, Encodes Secreted-type Protein with Conserved Cysteine Residues. Int. J. Oncol. 23, 235-241 (2003).
31. Katoh, M., Katoh, M. IGSF11 Gene, Frequently Up-regulated in Intestinal-type Gastric Cancer, Encodes Adhesion Molecule Homologous to CXADR, FLJ22415 and ESAM. Int. J. Oncol. 23, 525-531 (2003).
32. Sgroi, D. C., Teng, S., Robinson, G., et al. In Vivo Gene Expression Profile Analysis of Human Breast Cancer Progression. Cancer Res. 59, 5656-5661 (1999).
33. Alevizos, I., Mahadevappa, M., Zhang, X., et al. Oral Cancer In Vivo Gene Expression Profiling Assisted by Laser Capture Microdissection and Microarray Analysis. Oncogene 20, 6196-6204 (2001).
34. Hasegawa, S., Furukawa, Y., Li, M., et al. Genome-wide Analysis of Gene Expression in Intestinal-type Gastric Cancers Using a Complementary DNA Microarray Representing 23,040 Genes. Cancer Res. 62, 7012-7017 (2002).
35. Katoh, M., Katoh, M. MGC9753 Gene, Located Within PPP1R1B-STARD3-ERBB2- GRB7 Amplicon on Human Chromosome 17q12, Encodes Seven-transmembrane Receptor with Extracellular Six-cystein Domain. Int. J. Oncol. 22, 1369-1374 (2003).
36. Katoh, M., Katoh, M. Evolutionary Recombination Hotspot Around GSDML-GSDM Locus is Closely Linked to Oncogenomic Recombination Hotspot Around PPP1R1B-ERBB2-GRB7 Amplicon. Int. J. Oncol. 24, 757-763 (2004).
37. Katoh, M., Katoh, M. FLJ10261 Gene, Located Within the CCND1-MS1 Locus on Human Chromosome 11q13, Encodes Eight-transmembrane Protein Homologous To C12orf3, C11orf25, and Flj34272 Gene Products. Int. J. Oncol. 22, 1375-1381 (2003).
38. Katoh, M., Katoh, M. Evolutionary Conservation Of CCND1-ORAOV1-FGF19-FGF4 Locus from Zebrafish to Human. Int. J. Mol. Med. 12, 45-50 (2003).
39. Pollack, J. R., Sorlie, T., Perou, C. M., et al. Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors. Proc. Natl. Acad. Sci. USA 99, 12963-12968 (2002).
40. Hyman, E., Kauraniemi, P., Hautaniemi, S., et al. Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer. Cancer Res. 62, 6240-6245 (2002).
41. Ishkanian, A. S., Malloff, C. A., Watson, S. K., et al. A Tiling Resolution DNA Microarray with Complete Coverage of the Human Genome. Nat. Genet. 36, 299-303 (2004).
42. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., et al. Use of Proteomic Patterns in Serum to Identify Ovarian Cancer. Lancet 359, 572-577 (2002).
43. Yazidi-belkoura, I. E., Adriaenssens, E., Vercoutter-Edouart, A. S., et al. Proteomics of Breast Cancer: Outcomes and Prospects. Technol. Cancer Res. Treat. 1, 287-296 (2002).
44. Rosty, C., Goggins, M. Identification of Differentially Expressed Proteins in Pancreatic Cancer using a Global Proteomic Approach. Methods Mol. Med. 103, 189-197 (2005).
45. Vlahou, A., Schellhammer, P. F., Mendrinos, S., et al. Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine. Am. J. Pathol. 158, 1491-502 (2001).
46. Lyons-Weiler, J., Patel, S., Bhattacharya, S. A Classification-based Machine Learning Approach for the Analysis of Genome-wide Expression Data. Genome Res. 13, 503-512 (2003).
47. Liu, E. T. Classification of Cancers by Expression Profiling. Curr. Opin. Genet. Dev. 13, 97-103 (2003).
48. Lauren, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-called Intestinal-type Carcinoma. Acta. Pathol. Microbiol. Scand. 64, 31-49 (1965).
49. Katoh, M. Trefoil Factors and Human Gastric Cancer. Int. J. Mol. Med. 12, 3-9 (2003).
50. Schena, M., Heller, R. A., Theriault, T. P., et al. Microarrays: Biotechnology's Discovery Platform for Functional Genomics. Trends Biotechnol. 16, 301-306 (1998).
51. Zweiger, G. Knowledge Discovery in Gene-expression-microarray Data: Mining the Information Output of the Genome. Trends Biotechnol. 17, 429-436 (1999).
52. van't Veer, L. J., Dai, H., van de Vijver, M. J., et al. Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer. Nature 415, 530-536 (2002).
53. van de Vijver, M. J., He, Y. D., van't Veer, L. J., et al. A Gene-expression Signature as a Predictor of Survival in Breast Cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
54. Wellmann, A., Wollscheid, V., Lu, H., et al. Analysis of Microdissected Prostate Tissue with ProteinChip Arrays - A way to New Insights into Carcinogenesis and to Diagnostic Tools. Int. J. Mol. Med. 9, 341-347 (2002).
55. Gharib, T. G., Chen, G., Wang, H., et al. Proteomic Analysis of Cytokeratin Isoforms Uncovers Association with Survival in Lung Adenocarcinoma. Neoplasia 4, 440-448 (2002).
56. McDonald, S. L., Edington, H. D., Kirkwood, J. M., Becker, D. Expression Analysis of Genes Identified by Molecular Profiling of VGP Melanomas and MGP Melanoma-positive Lymph Nodes. Cancer Biol. Ther. 3, 110-120 (2004).
57. Callagy, G., Pharoah, P., Chin, S. F., et al. Identification and Validation of Prognostic Markers in Breast Cancer with the Complementary use of Array-CGH and Tissue Microarrays. J. Pathol. 205, 388-396 (2005).
58. Michiels, S., Koscielny, S., Hill, C. Prediction of Cancer Outcome With Microarrays: A Multiple Random Validation Strategy. Lancer 365, 488-492 (2005).
59. Kihara, C., Tsunoda, T., Tanaka, T., et al. Prediction of Sensitivity of Esophageal Tumors to Adjuvant Chemotherapy by cDNA Microarray Analysis of Gene-expression Profiles. Cancer Res. 61, 6474-6479 (2001).
60. Wong, Y. F., Selvanayagam, Z. E., Wei, N., et al. Expression Genomics of Cervical Cancer: Molecular Classification and Prediction of Radiotherapy Response by DNA Microarray. Clin. Cancer Res. 9, 5486-5492 (2003).
61. Reichert, J. M., Rosensweig, C. J., Faden, L. B., Dewitz, M. C. Monoclonal Antibody Success in Clinic. Nat. Biotech. 23, 1073-1078 (2005).
62. Krause D. S., Van Etten, R. A. Tyrosine Kinases as Targets for Cancer Therapy. N. Engl. J. Med. 353, 172-187 (2005).
63. Sagara, N., Katoh, M. Mitomycin C Resistance Induced by TCF-3 Overexpression in Gastric Cancer Cell Line MKN28 is Associated With DT-diaphorase Down-regulation. Cancer Res. 60, 5959-5962 (2000).
64. Zembutsu, H., Ohnishi, Y., Tsunoda, T., et al. Genome-wide cDNA Microarray Screening to Correlate Gene Expression Profiles with Sensitivity of 85 Human Cancer Xenografts to Anticancer Drugs. Cancer Res. 62, 518-527 (2002).
65. Stam, R. W., den Boer, M. L., Meijerink, J. P., et al. Differential mRNA Expression of Ara-C-metabolizing Enzymes Explains Ara-C Sensitivity in MLL. Gene-rearranged Infant Acute Lymphoblastic Leukemia. Blood 101, 1270-1276 (2003).
66. Bubendorf, L., Kolmer, M., Kononen, J., et al. Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays. J. Natl. Cancer Inst. 91, 1758-1764 (1999).
67. Mousses, S., Wagner, U., Chen, Y., et al. Failure of Hormone Therapy in Prostate Cancer Involves Systematic Restoration of Androgen Responsive Genes and Activation of Rapamycin Sensitive Signaling. Oncogene 20, 6718-6723 (2001).
68. Chen, C. D., Welsbie, D. S., Tran, C., et al. Molecular Determinants of Resistance to Antiandrogen Therapy. Nat. Med. 10, 33-39 (2004).
69. Gruvberger, S., Ringner, M., Chen, Y., et al. Estrogen Receptor Status in Breast Cancer is Associated with Remarkably Distinct Gene Expression Patterns. Cancer Res. 61, 5979-5984 (2001).
70. Sorlie, T., Perou, C. M., Tibshirani, R., et al. Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874 (2001).
71. Kakiuchi, S., Daigo, Y., Ishikawa, N., et al. Prediction of Sensitivity of Advanced Non-small Cell Lung Cancers to Gefitinib (Iressa, ZD1839). Hum. Mol. Genet. 13, 3029-3043 (2004).
72. Tsurutani, J., West, K. A., Sayyah, J., Gills, J. J., Dennis, P. A. Inhibition of the Phosphatidylinositol 3-kinase/Akt/Mammalian Target of Rapamycin Pathway but not the MEK/ERK Pathway Attenuates Laminin-mediated Small Cell Lung Cancer Cellular Survival and Resistance to Imatinib Mesylate or Chemotherapy. Cancer Res. 65, 8423-8432 (2005).
73. Wilkinson, G. R. Drug Metabolism and Variability Among Patients in Drug Response. N. Engl. J. Med. 352, 2211-2221 (2005).
74. Need, A. C., Motulsky, A. G., Goldstein, D. B. Priorities and Standards in Pharmacogenetic Research. Nat. Genet. 37, 671-681 (2005).